Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib

Cancer Letters

Volumn 370, Issue 2, 2016, Pages 242-249

  Houessinon, Aline ^a   Gicquel, Albane ^a   Bochereau, Flora ^a   Louandre, Christophe ^a   Nyga, Rémy ^a   Godin, Corinne ^a,c   Degonville, James ^a   Fournier, Emma ^a   Saidak, Zuzana ^a   Drullion, Claire ^c,d,e   Barbare, Jean Claude ^b   Chauffert, Bruno ^b   François, Catherine ^b   Pluquet, Olivier ^c,d,e   Galmiche, Antoine ^a,b  

^a AMIENS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^c UNIV LILLE   (France)

^d INSTITUT DE BIOLOGIE DE LILLE   (France)

^e INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Alpha fetoprotein; Hepatocellular carcinoma; Proteostasis; Sorafenib; Unfolded Protein Response (UPR)

Indexed keywords

ALPHA FETOPROTEIN; MESSENGER RNA; NUCLEASE; PHOSPHOTRANSFERASE; PKR LIKE ER KINASE; REGULATED INOSITOL REQUIRING ENZYME 1ALPHA; SORAFENIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CARBANILAMIDE DERIVATIVE; DNA BINDING PROTEIN; NICOTINAMIDE; PROTEIN; REGULATORY FACTOR X TRANSCRIPTION FACTORS; TRANSCRIPTION FACTOR;

ARTICLE; CARCINOMA CELL; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; ENZYME ACTIVATION; ENZYME REGULATION; GOLGI COMPLEX; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN HOMEOSTASIS; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS REGULATION; UNFOLDED PROTEIN RESPONSE; ANALOGS AND DERIVATIVES; BIOSYNTHESIS; CARCINOMA, HEPATOCELLULAR; CELL SURVIVAL; DRUG EFFECTS; HOMEOSTASIS; LIVER NEOPLASMS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DNA-BINDING PROTEINS; HOMEOSTASIS; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEINS; TRANSCRIPTION FACTORS; UNFOLDED PROTEIN RESPONSE;

EID: 84949509421     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.10.032     Document Type: Article

References (28)

1. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med 2008, 359:378-390.
2. Llovet J.M., Hernandez-Gea V. Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design. Clin. Cancer Res 2014, 20:2072-2079.
3. Galmiche A., Chauffert B., Barbare J.C. New biological perspectives for the improvement of the activity of Sorafenib against Hepatocellular Carcinoma. Cancer Lett 2014, 346:159-162.
4. Hollebecque A., Malka D., Ferté C., Ducreux M., Boige V. Systemic treatment of advanced hepatocellular carcinoma: from desillusions to new horizons. Eur. J. Cancer 2015, 51:327-339.
5. Peterson M.L., Ma C., Spear B.T. Zhx2 and Zbtb20: novel regulators of postnatal alpha-fetoprotein repression and their potential role in gene reactivation during liver cancer. Semin. Cancer Biol 2011, 21:21-27.
6. Nakao K., Ichikawa T. Recent topics on α-fetoprotein. Hepatol. Res 2013, 43:820-825.
7. Kawaoka T., Aikata H., Murakami E., Nakahara T., Naeshiro N., Tanaka M., et al. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology 2012, 83:192-200.
8. Personeni N., Bozzarelli S., Pressiani T., Rimassa L., Tronconi M.C., Sclafani F., et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J. Hepatol 2012, 57:101-107.
9. Liu L., Cao Y., Chen C., Zhang X., McNabola A., Wilkie D., et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006, 66:11851-11858.
10. Davis M.I., Hunt J.P., Herrgard S., Ciceri P., Wodicka L.M., Pallares G., et al. Comprehensive analysis of kinase inhibitor selectivity. Nat. Biotechnol 2011, 29:1046-1051.
11. Rahmani M., Davis E.M., Crabtree T.R., Habibi J.R., Nguyen T.K., Dent P., et al. The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol. Cell. Biol 2007, 27:5499-5513.
12. + ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Mol. Cancer Ther 2012, 11:2610-2620.
13. Dixon S.J., Patel D.N., Welsch M., Skouta R., Lee E.D., Hayano M., et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. Elife 2014, 3:e02523.
14. Hetz C., Chevet E., Oakes S.A. Proteostasis control by the unfolded protein response. Nat. Cell Biol 2015, 17:829-838.
15. Chevet E., Hetz C., Samali A. Endoplasmic reticulum stress-activated cell reprogramming in oncogenesis. Cancer Discov 2015, 5:586-597.
16. Pluquet O., Dejeans N., Bouchecareilh M., Lhomond S., Pineau R., Higa A., et al. Posttranscriptional regulation of PER1 underlies the oncogenic function of IREα. Cancer Res 2013, 73:4732-4743.
17. Ezzoukhry Z., Louandre C., Trécherel E., Godin C., Chauffert B., Dupont S., et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int. J. Cancer 2012, 131:2961-2969.
18. Galmiche A., Ezzoukhry Z., François C., Louandre C., Sabbagh C., Nguyen-Khac E., et al. BAD, a pro-apoptotic member of the Bcl2 family, is a potential therapeutic target in hepatocellular carcinoma. Mol. Cancer Res 2010, 8:1116-1125.
19. Louandre C., Ezzoukhry Z., Godin C., Barbare J.C., Mazière J.C., Chauffert B., et al. Iron-dependent cell death of hepatocellular carcinoma cells. Exposed to Sorafenib. Int. J. Cancer 2013, 133:1732-1742.
20. Castillo J., Erroba E., Perugorría M.J., Santamaría M., Lee D.C., Prieto J., et al. Amphiregulin contributes to the transformed phenotype of human hepatocellular carcinoma cells. Cancer Res 2006, 66:6129-6138.
21. Yoshida H., Haze K., Yanagi H., Yura T., Mori K. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J. Biol. Chem 1998, 273:33741-33749.
22. Ri M., Tashiro E., Oikawa D., Shinjo S., Tokuda M., Yokouchi Y., et al. Identification of Toyocamycin, an agent cytotoxic for multiple myeloma cells, as a potent inhibitor of ER stress-induced XBP1 mRNA splicing. Blood Cancer J. 2012, 2:e79.
23. Axten J.M., Medina J.R., Feng Y., Shu A., Romeril S.P., Grant S.W., et al. Discovery of 7-methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK). J. Med. Chem 2012, 55:7193-7207.
24. Maurel M., Chevet E., Tavernier J., Gerlo S. Getting RIDD of RNA: IRE1 in cell fate regulation. Trends Biochem. Sci 2014, 39:245-254.
25. Yang X., Zhang Y., Zhang L., Zhang L., Mao J. Silencing alpha-fetoprotein expression induces growth arrest and apoptosis in human hepatocellular cancer cell. Cancer Lett 2008, 271:281-293.
26. Meng W., Li X., Bai Z., Li Y., Yuan J., Liu T., et al. Silencing alpha-fetoprotein inhibits VEGF and MMP-2/9 production in human hepatocellular carcinoma cell. PLoS ONE 2014, 9:e90660.
27. Dejeans N., Manié S., Hetz C., Bard F., Hupp T., Agostinis P., et al. Addicted to secrete - novel concepts and targets in cancer therapy. Trends Mol. Med 2014, 20:242-250.
28. Obenauf A.C., Zou Y., Ji A.L., Vanharanta S., Shu W., Shi H., et al. Therapy-induced tumour secretomes promote resistance and tumour progression. Nature 2015, 20:368-372.